Aranäs C, Edvardsson CE, Shevchouk OT et al (2023) Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 93:104642

Aranäs C, Caffrey A, Edvardsson CE et al (2025) Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and Amylin in male rats. Br J Pharmacol 182:1292–1305

PubMed  Google Scholar 

Arillotta D, Floresta G, Guirguis A et al (2023) GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain Sci 13:1503

CAS  PubMed  PubMed Central  Google Scholar 

Arillotta D, Floresta G, Papanti Pelletier GD et al (2024) Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sci 14:617

CAS  PubMed  PubMed Central  Google Scholar 

Badulescu S, Tabassum A, Le GH et al (2024) Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review. Physiol Behav 283:114622

Besheer J, Hodge CW (2005) Pharmacological and anatomical evidence for an interaction between mGluR5-and GABAA α1-containing receptors in the discriminative stimulus effects of ethanol. Neuropsychopharmacology 30:747–757

CAS  PubMed  Google Scholar 

Bolin BL, Alcorn JL III, Reynolds AR et al (2016) Human drug discrimination: A primer and methodological review. Exp Clin Psychopharmacol 24:214

PubMed  PubMed Central  Google Scholar 

Bremmer MP, Hendershot CS (2024) Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders. J Stud Alcohol Drugs 85:5–10

PubMed  PubMed Central  Google Scholar 

Brunchmann A, Thomsen M, Fink-Jensen A (2019) The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol Behav 206:232–242

CAS  PubMed  PubMed Central  Google Scholar 

Bruns VN, Tressler EH, Vendruscolo LF et al (2024) IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol Res 207:107312

Chao AM, Tronieri JS, Amaro A, Wadden TA (2023) Semaglutide for the treatment of obesity. Trends Cardiovasc Med 33:159–166

CAS  PubMed  Google Scholar 

Chuong V, Farokhnia M, Khom S et al (2023) The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8:e170671

PubMed  PubMed Central  Google Scholar 

Delvadia P, Dhote V, Mandloi AS et al (2025) Dual GLP-1 and GIP agonist Tirzepatide exerted neuroprotective action in a parkinson’s disease rat model. ACS Chem Neurosci 16:818–825

CAS  PubMed  Google Scholar 

Dickson SL, Shirazi RH, Hansson C et al (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812–4820

CAS  PubMed  PubMed Central  Google Scholar 

Dossat AM, Lilly N, Kay K, Williams DL (2011) Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 31:14453–14457

CAS  PubMed  PubMed Central  Google Scholar 

Egecioglu E, Engel JA, Jerlhag E (2013) The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS ONE 8:e69010

CAS  PubMed  PubMed Central  Google Scholar 

Finan B, Yang B, Ottaway N et al (2012) Targeted Estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847–1856

CAS  PubMed  PubMed Central  Google Scholar 

Fink-Jensen A, Vilsbøll T (2016) Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder? Nord J Psychiatry 70:561–562

PubMed  Google Scholar 

Fink-Jensen A, Wörtwein G, Klausen MK et al (2024) Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male Vervet monkeys. Psychopharmacology 242:1–8

Geisler CE, Antonellis MP, Trumbauer W et al (2023) Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metabolism 25:56–67

CAS  Google Scholar 

Grant KA, Bennett AJ (2003) Advances in nonhuman primate alcohol abuse and alcoholism research. Pharmacol Ther 100:235–255

CAS  PubMed  Google Scholar 

Hayes MR, Schmidt HD (2016) GLP-1 influences food and drug reward. Curr Opin Behav Sci 9:66–70

PubMed  PubMed Central  Google Scholar 

Hayes MR, Skibicka KP, Grill HJ (2008) Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149:4059–4068

CAS  PubMed  PubMed Central  Google Scholar 

Heilig M, Witkiewitz K, Ray LA et al (2024) Novel medications for problematic alcohol use. J Clin Invest 134:e172889

Hendershot CS, Bremmer MP, Paladino MB et al (2025) Once-Weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry

Jaramillo AA, Randall PA, Frisbee S, Besheer J (2016) Modulation of sensitivity to alcohol by cortical and thalamic brain regions. Eur J Neurosci 44:2569–2580

PubMed  PubMed Central  Google Scholar 

Jaramillo AA, Randall PA, Stewart S et al (2018a) Functional role for cortical-striatal circuitry in modulating alcohol self-administration. Neuropharmacology 130:42–53. https://doi.org/10.1016/j.neuropharm.2017.11.035

CAS  PubMed  Google Scholar 

Jaramillo AA, Van Voorhies K, Randall PA, Besheer J (2018b) Silencing the insular-striatal circuit decreases alcohol self-administration and increases sensitivity to alcohol. Behav Brain Res 348:74–81

CAS  PubMed  PubMed Central  Google Scholar 

Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple–hormone-receptor agonist Retatrutide for obesity—a phase 2 trial. N Engl J Med 389:514–526

CAS  PubMed  Google Scholar 

Jerlhag E (2023) The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol 14:1063033

CAS  PubMed  PubMed Central  Google Scholar 

Jerlhag E (2025) GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology 166:bqaf028

CAS  PubMed  PubMed Central  Google Scholar 

Kaur M, Misra S (2024) A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol 80:669–676

CAS  PubMed  Google Scholar 

King AC, McNamara PJ, Hasin DS, Cao D (2014) Alcohol challenge responses predict future alcohol use disorder symptoms: a 6-year prospective study. Biol Psychiatry 75:798–806

PubMed  Google Scholar 

King AC, Hasin D, O’Connor SJ et al (2016) A prospective 5-year re-examination of alcohol response in heavy drinkers progressing in alcohol use disorder. Biol Psychiatry 79:489–498

PubMed  Google Scholar 

Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A (2022) The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 179:625–641

PubMed  Google Scholar 

Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238

PubMed  Google Scholar 

Koob GF, Kenneth Lloyd G, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 8:500–515

CAS  PubMed  PubMed Central  Google Scholar 

Kooij KL, Koster DIj, Eeltink E et al (2024) GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurosci Appl 3:103925

PubMed  Google Scholar 

Leggio L, Hendershot CS, Farokhnia M et al (2023) GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med 29:2993–2995

CAS  PubMed  Google Scholar 

Lovelock DF, Tyler RE, Besheer J (2021) Interoception and alcohol: mechanisms, networks, and implications. Neuropharmacology 200:108807

CAS  PubMed  PubMed Central  Google Scholar 

Marty VN, Farokhnia M, Munier JJ et al (2020) Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front Neurosci 14:599646

PubMed  PubMed Central  Google Scholar 

Meloni A, DeYoung M, Lowe C, Parkes D (2013) GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metabolism 15:15–27

CAS  Google Scholar 

Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280

CAS  PubMed